<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00439803</url>
  </required_header>
  <id_info>
    <org_study_id>AVX601-001</org_study_id>
    <nct_id>NCT00439803</nct_id>
  </id_info>
  <brief_title>A Clinical Trial of an Alphavirus Replicon Vaccine for Cytomegalovirus (CMV)</brief_title>
  <acronym>CMV</acronym>
  <official_title>A Single-Site, Phase 1, Double-Blind, Safety and Immunogenicity Trial of an Alphavirus Replicon Vaccine Expressing Cytomegalovirus Genes (AVX601) in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AlphaVax, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AlphaVax, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      AVX601, a bivalent alphavirus replicon vaccine expressing three CMV proteins (gB, pp65 and&#xD;
      IE1) is a candidate vaccine against cytomegalovirus (CMV).&#xD;
&#xD;
      The objectives of this Phase 1 study are to test the safety of the vaccine and the immune&#xD;
      response to the vaccine in healthy volunteers who have not previously been infected with CMV.&#xD;
      Volunteers will be assigned by randomization to receive either the vaccine or an inactive&#xD;
      substance (placebo) by injections in each arm on three occasions over 6 months. The study&#xD;
      will last 12 months and will have a total of 12 visits.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, placebo-controlled Phase 1 study of the safety and&#xD;
      immunogenicity of AVX601 vaccine at two dosage levels and two routes of administration in&#xD;
      healthy volunteers conducted at a single research center. A total of 40 participants will be&#xD;
      enrolled into two groups of 20 participants each. Within each group, participants will be&#xD;
      randomized to receive the active vaccine by IM injection (N = 8) or SC injection (N = 8) or&#xD;
      to receive a placebo by IM injection (N = 2) or SC injection (N = 2). Each participant will&#xD;
      receive a total of six injections of vaccine or placebo, two at each visit at Weeks 0, 8 and&#xD;
      24, administered by a study nurse in an outpatient setting, and will be followed for 12&#xD;
      months after the first immunization. Safety data will include local and systemic&#xD;
      reactogenicity after each dose of vaccine, collected in a systematic format using a subject&#xD;
      memory aid and a standard grading scale, specific safety laboratory parameters and general&#xD;
      AEs. Immunogenicity data will be obtained by collecting blood at defined time points before&#xD;
      and after immunization and separating serum (for measurement of antibodies to CMV by ELISA&#xD;
      and neutralization assays and to the vaccine vector by a VRP neutralization assay) and&#xD;
      peripheral blood mononuclear cells (PMBC) (for measurement of cellular immune responses to&#xD;
      CMV peptides).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>evaluate safety of AVX601 based on teh frequency of Grade 2,3,or 4 systemic reactogenicity events</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>evaluate the immunogenicity of AVX601 in healthy volunteers after 3 doses of vaccine</measure>
    <time_frame>15 months</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Cytomegalovirus Infections</condition>
  <arm_group>
    <arm_group_label>T1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>C1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>T2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>C2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>T3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>C3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>T4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>C4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AVX601</intervention_name>
    <description>3 doses of AVX601 at 1e7 IU given at T=0, 8, 24 weeks via the IM route</description>
    <arm_group_label>T1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>3 doses of placebo given at T=0, 8, 24 weeks via the IM route</description>
    <arm_group_label>C1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AVX601</intervention_name>
    <description>3 doses of AVX601 at 1e7 IU given at T=0, 8, 24 weeks via the SC route</description>
    <arm_group_label>T2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>3 doses of placebo given at T=0, 8, 24 weeks via the SC route</description>
    <arm_group_label>C2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AVX601</intervention_name>
    <description>3 doses of AVX601 at 1e8 IU given at T=0, 8, 24 weeks via the IM route</description>
    <arm_group_label>T3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AVX601</intervention_name>
    <description>3 doses of placebo given at T=0, 8, 24 weeks via the IM route</description>
    <arm_group_label>C3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AVX601</intervention_name>
    <description>3 doses of AVX601 at 1e8 IU given at T=0, 8, 24 weeks via the SC route</description>
    <arm_group_label>T4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>3 doses of placebo given at T=0, 8, 24 weeks via the SC route</description>
    <arm_group_label>C4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Between 18 and 45 years of age, inclusive&#xD;
&#xD;
          2. Good general health without significant physical examination findings or clinically&#xD;
             significant abnormal laboratory results&#xD;
&#xD;
          3. Available to participate for the entire study period of approximately 12 months&#xD;
&#xD;
          4. For women of childbearing potential, a negative urine pregnancy test at screening and&#xD;
             before each immunization, and agreement to consistently use contraception from 28 days&#xD;
             prior to enrollment until the last protocol visit, for sexual activity that could lead&#xD;
             to pregnancy&#xD;
&#xD;
          5. Acceptable laboratory parameters:&#xD;
&#xD;
               -  negative CMV serology&#xD;
&#xD;
               -  hemoglobin ≥ 11.2 g/dL for women, ≥ 12.8 g/dL for men&#xD;
&#xD;
               -  white blood cell count 3,300 - 12,000 cells/mm3&#xD;
&#xD;
               -  platelet count 125,000 - 550,000/mm3&#xD;
&#xD;
               -  alanine aminotransferase (ALT) within normal range for study laboratory&#xD;
&#xD;
               -  serum creatinine within normal range for study laboratory&#xD;
&#xD;
               -  normal urine dipstick (negative glucose, negative hemoglobin, and negative or&#xD;
                  trace protein)&#xD;
&#xD;
               -  negative hepatitis B virus (HBV) and hepatitis C virus (HCV) blood tests&#xD;
&#xD;
               -  negative HIV blood test&#xD;
&#xD;
          6. Willingness to have blood stored for up to 10 years for use in additional assays to&#xD;
             evaluate immune responses to CMV or the alphavirus vector if such assays become&#xD;
             available&#xD;
&#xD;
          7. Willingness to participate in the study as evidenced by signed informed consent&#xD;
             obtained before screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Venous access deemed inadequate for the phlebotomy demands of the study&#xD;
&#xD;
          2. Women who are breast feeding&#xD;
&#xD;
          3. In female subjects, a positive urine pregnancy test at screening or on the day of any&#xD;
             vaccine injection&#xD;
&#xD;
          4. Receipt of any vaccine within 30 days prior to enrollment&#xD;
&#xD;
          5. Use of any investigational agent within 30 days prior to enrollment&#xD;
&#xD;
          6. Receipt of immunoglobulin or blood products within 60 days prior to enrollment&#xD;
&#xD;
          7. Use of cytotoxic medications within 6 months prior to enrollment&#xD;
&#xD;
          8. Use of systemic corticosteroids within 6 months prior to enrollment (except that&#xD;
             participants who have completed a course of prednisone, at up to 20 mg per day for up&#xD;
             to 7 days, at least 1 month prior to enrollment are eligible for enrollment)&#xD;
&#xD;
          9. History of serious adverse reactions to any vaccine, including anaphylaxis and related&#xD;
             symptoms such as hives, respiratory difficulty, angioedema or abdominal pain&#xD;
&#xD;
         10. History of immunodeficiency or autoimmune disease&#xD;
&#xD;
         11. History of diabetes mellitus&#xD;
&#xD;
         12. History of splenectomy&#xD;
&#xD;
         13. History of malignancy within the last 3 years (except that participants with a&#xD;
             diagnosis of basal cell carcinoma of the skin are eligible for enrollment)&#xD;
&#xD;
         14. Psychiatric condition that may interfere with the ability to comply with the protocol&#xD;
             requirements. Specifically excluded are persons with history of psychosis within the&#xD;
             past 3 years or history of suicidal attempt or gesture within the past 3 years.&#xD;
&#xD;
         15. History of medical, occupational or family problems as a result of alcohol or illicit&#xD;
             drug use during the past 12 months&#xD;
&#xD;
         16. Any condition which leads the investigator to believe that the participant cannot&#xD;
             comply with the protocol requirements or that may place the participant at an&#xD;
             unacceptable risk for participation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert A Olmsted, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>AlphaVax, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cincinnati Center for Clinical Research</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.alphavax.com</url>
    <description>AlphaVax Human Vaccines, Inc.</description>
  </link>
  <verification_date>November 2008</verification_date>
  <study_first_submitted>February 23, 2007</study_first_submitted>
  <study_first_submitted_qc>February 23, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2007</study_first_posted>
  <last_update_submitted>November 7, 2008</last_update_submitted>
  <last_update_submitted_qc>November 7, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 10, 2008</last_update_posted>
  <responsible_party>
    <name_title>Robert A. Olmsted, Ph.D.</name_title>
    <organization>AlphaVax, Inc.</organization>
  </responsible_party>
  <keyword>CMV</keyword>
  <keyword>cytomegalovirus</keyword>
  <keyword>Alphavirus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytomegalovirus Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

